This table lists all the major pharma collaborations, acquisitions and mergers agreed during November 2014.
For an indepth analysis of these deals, read ‘Pharma deals during November 2014’
|
Licensor acquired / licensee acquirer |
Product / technology |
Deal type |
Headline ($m) |
| Allergan / Actavis | Dermatology / ophthalmology portfolio | Company acquisition | 66,000 |
| Omega Pharma / Perrigo | OTC portfolio | Company acquisition | 4,500 |
| Cystic Fibrosis Foundation /Royalty Pharma | Vertex’s CF portfolio | Royalty stream acquisition | 3,300 |
| Indivior / Reckitt Benckiser | Pharma business unit | Business unit divestment | 3,200 |
| Almirall / AstraZeneca | Eklira and Duaklir | Business unit acquisition | 3,075 |
| Pfizer / Merck KGaA | PD-L1 and PD-1 CP inhibitors | Co-development and co-marketing alliance | 2,850 |
| UCB (Kremers Urban Pharma) /Advent International and Avista Capital Partners | Generics portfolio | Company divestment | 1,530 |
| Proteostasis Therapeutics / Astellas | Therapeutics modulating Unfolded Protein Response – multiple programmes | Discovery collaboration | 1,200 |
| Intacia / Servier | ICTA 650 (injection free GLP-1 agonist) | Licence | 1,051 |
| Geron Corporation / J&J (Janssen) | GRN163L, Imetelstat and tolerase inhibitor | Licence | 935 |
| Prosensa / BioMarin | Drisapersen – for Duchenne muscular dystrophy | Company acquisition | 840 |
| Galecto Biotech / BMS | TD139 galectin-3 inhibitor for Idiopathic pulmonary fibrosis | Option | 444 |
| AstraZeneca / Aegerion | Myalet (metreleptin) injection for leptin deficiency | Product acquisition | 325 |
| Transposagen Biopharmaceuticals/ J&J (Janssen) | Allogeneic Chimeric Antigen Receptor T-cells (CAR-T) therapies | Licence & research collaboration | 292 |
| Modern Biosciences / J&J (Janssen Biotech) | Bone protection compounds in RA | Research collaboration | 275 |
| Definiens / AstraZeneca (through MedImmune) | Tissue Phenomics Dx oncology biomarkers | Company acquisition | 150 |
| Knight Therapeutics / Gilead Sciences | Priority review voucher for Miltefosine | Acquisition of voucher | 125 |
| AVEO Oncology / Ophthotech Corporation | VEGF tyrosine kinase inhibitor tivozanib | Research and exclusive option to license | 106 |
| University of Michigan / PDL Biopharma | Cerdelga (eliglustat) sold by Vertex | Acquisition 75% royalty stream | 66 |
| Five Prime Therapeutics / BMS | FPA008 mAb inhibits (CSF1R) to be combined with nivolumab (PD-1 check-point inhibitor) | Research collaboration | 30 |
